Costs of unstructured investigation of unexplained syncope: insights from a micro-costing analysis of the observational PICTURE registry

Nils Edvardsson1*, Claudia Wolff2, Stelios Tsintzos3, Guido Rieger4, and Nicholas J. Linker5

1Sahlgrenska Academy at Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden; 2Medtronic European Headquarters, Tolochenaz, Switzerland; 3Medtronic Global Headquarters, Mounds View, MN, USA; 4Medtronic Bakken Research Center, Maastricht, The Netherlands; and 5The James Cook University Hospital, Middlesbrough, UK

Received 23 October 2014; accepted after revision 30 December 2014; online publish-ahead-of-print 10 March 2015

Aims

The observational PICTURE (Place of Reveal In the Care pathway and Treatment of patients with Unexplained Recurrent Syncope) registry enrolled 570 patients with unexplained syncope, documented their care pathway and the various tests they underwent before the insertion of an implantable loop recorder (ILR). The aims were to describe the extent and cost of diagnostic tests performed before the implant.

Methods and results

Actual costs of 17 predefined diagnostic tests were characterized based on a combination of data from PICTURE and a micro-costing study performed at a medium-sized UK university hospital in the UK. The median cost of diagnostic tests per patient was £1114 (95% CI £995–£1233). As many patients received more than the median number of tests, the mean expenditure per patient was higher with £1613 (95% CI £1494–£1732), and for 10% of the patients the cost exceeded £3539. Tests were frequently repeated, and early use of specific and expensive tests was common. In the 12% of patients with types of tests entirely within the recommendations for an initial evaluation before ILR implant, the mean cost was £710.

Conclusion

Important opportunities to reduce test-related costs before an ILR implant were identified, e.g. by more appropriate use of tests recommended in the initial evaluation, by decreasing repetition of tests, and by avoiding early use of specialized and expensive tests. A structured multidisciplinary approach would be the best model to achieve an optimal outcome.

Introduction

The investigation of syncope imposes a significant economic burden on society.1–3 Healthcare expenditure is substantial since syncope is a common symptom with a variety of potential underlying causes leading to patient visits to physicians, the emergency department, and to hospitalizations after syncope with or without associated trauma.3 Syncope was the fifth most common cause for an emergency department visit in the UK according to the Hospital Episode Statistics 2011–12.4

The diagnostic tests undertaken to find the cause of syncope are important drivers of the cost. Updated guidelines and/or consensus documents present evidence and recommendations on which investigations are most relevant and likely to lead to a diagnosis4–6 while at the same time less effective measures can be replaced. Guidelines are dynamic documents that are updated as new research produces evidence that justifies changes in recommendations. However, the dissemination and penetration of the messages of guidelines and expert consensus documents are far from satisfactory and clinical practice adapts slowly.7

Previous studies have reported substantial costs of evaluating syncope patients and have suggested the adoption of a more systematic patient care pathway.1,2,8,9 The observational PICTURE (Place of Reveal In the Care pathway and Treatment of patients...
What’s new?

- A microeconomic analysis of the evaluation of unexplained syncope patients identified important cost-saving opportunities.
- There were both over- and under-investigations relative to the current clinical guidelines, and the use of available tests can be more appropriate.
- The early use of specialized tests and the repetition of tests can be reduced.
- The messages of current guidelines have not been sufficiently implemented in real-life clinical practice of unexplained syncope.

with Unexplained Recurrent Syncope) registry reported that an apparent lack of structured care pathways leads to significant over-investigation of unexplained syncope before patients received an implantable loop recorder (ILR). Reasonably, this influenced the cost of evaluation of the patients, partly because tests could be repeated many times and also because patients undergo various expensive diagnostic tests with a low diagnostic yield. An earlier rather than a later ILR implant reduced the number of preimplant tests without reducing the diagnostic yield. The aims of the present microeconomic analysis—based on the large, international, PICTURE registry—were to provide costs of diagnostic tests.

Methods

The design, methods, and main results of the PICTURE registry have been previously reported. Briefly, 570 patients with recurrent, unexplained syncope were enrolled and the interpretation of the term ‘unexplained’ was left to the physicians’ discretion. Their median number of syncope episodes was 4 (inter-quartile range, IQR, 2–5), and 3 (IQR 2–4) of them occurred during the 2 years preceding the ILR implant. The median time interval between the first and last episode was 2 years (IQR 0–4). The purpose was to document the care pathway in patients eventually implanted with an ILR as well as to examine the diagnostic yield of the ILR. The study protocol complied with the Declaration of Helsinki and was approved by the relevant locally appointed ethics committee. All patients provided their informed consent. An important finding of PICTURE was that a large number of diagnostic tests were performed, many of them despite a low probability of providing a diagnosis. The present analysis focused on the preimplant diagnostic evaluation, while other costs, such as specialist visits in relation to syncope, admissions to the emergency room, and/or hospitalizations or those caused by severe trauma associated with syncope (defined as fracture or injury with bleeding), were not assessed.

The costs of diagnostic tests were collected from a medium-sized UK university hospital since only few costs of diagnostic tests were available from data sets such as the UK NHS reference costs. The costs of diagnostic tests from the micro-costing study and the NHS reference costs 2009/10, when available, were similar, as summarized in Table 1. The median and mean costs of diagnostic tests per patient were calculated as the total number of tests recorded in the PICTURE registry multiplied by the estimated cost of the test in the micro-costing study.

| Table 1 Costs of tests |
|------------------------|
| Test                  | Costs | Patients tested (%) |
| PICTURE study         | Syncope costing study | National reference costs 2009/10 |
| Standard electrocardiogram | £37  | £33 | 98 |
| Echocardiography       | £47  | £32 | 86 |
| Basic laboratory tests | £24  | –  | 86 |
| Ambulatory ECG monitoring | £118 | £60 | 67 |
| In-hospital ECG monitoring | £42  | £60 | 55 |
| Exercise testing       | £78  | £75 | 52 |
| Orthostatic blood pressure movements | £11  | –  | 48 |
| Neurological or psychiatric evaluation | £111 | –  | 47 |
| MRI or CT scan         | £149 | £77–£244 | 47 |
| Carotid sinus massage  | £55  | –  | 36 |
| EEG                    | £180 | –  | 39 |
| TILT test              | £100 | –  | 35 |
| Electrophysiology testing | £1392 | –  | 25 |
| Coronary angiography   | £1285 | –  | 23 |
| External loop recording | £147 | –  | 12 |
| ‘Other tests’ = outpatient consultation | £163 | –  | 9 |
| Adenosine triphosphate (ATP) test | £70 | –  | 3 |

The micro-costing study of each individual test was based on a combination of existing hospital costs and original data collection. For each test, direct and indirect costs as well as overhead costs were calculated. This involved building an understanding of the typical process of conducting a diagnostic test as well as the associated level of direct resource input regarding the level of direct staff input based on the staff grade and time spent on the key tasks within a standard procedure, any relevant consumables, e.g. drugs and ECG electrodes, and the equipment used. Five cost components were identified (Figure 1): (i) labour (direct pay costs). A 21% on-cost was added to reflect national insurance and superannuation contributions, unless otherwise stated. (ii) Materials and disposables (direct non-pay costs). (iii) Departmental overheads (indirect departmental costs). (iv) Capital equipment costs including direct clinical equipment such as machinery (e.g. the ECG machine, CT scan, etc.). To understand depreciation and maintenance costs, the following formula was used: average cost per test = annual depreciation or maintenance cost/total no. of tests per annum. (v) Corporate overhead costs were added based on the current level of contribution required within the hospital, which according to the selected hospital finance department was 30%. This contribution covered the rates, rents, and other corporate functions such as finance, human resources, and information technology, and was...
Results

Patient demographics, concomitant diseases, and the first and last specialist who were visited before the ILR implant are presented in Table 2. As many as 70% of the patients had been hospitalized for syncope, 36% had suffered severe trauma defined as fracture and/or bleeding.

Median and mean costs of tests per patient

The total number of tests performed per patient is shown in Figure 2A and B. As shown in the box plot and histogram, there is a lot of variation in the number of tests per patient and some patients received a large number of tests. In fact, as many as 25% of the patients underwent more than 20 tests, whereas 10% had more than 31 tests done.

The distribution of the costs per patient mirrors the findings from the distribution of tests performed (Figure 3). Analogously to the test data, the costs per patient vary a lot, and the median 50% of the data is in the range of £569 – £2246. The median costs of diagnostic tests per patient were £1114 (95% CI £995 – £1232), while the mean expenditure per patient was substantially higher with £1613 (95% CI £995 – £1232). The costs for the most expensive 10% of the patients was £709 compared with £1113 (95% CI £995 – £1232). The costs for the most expensive 10% of the patients exceeded £3539 per patient.

Appropriate testing or not?

Since all patients had unexplained syncope at the time of the ILR implant, the diagnostic yield of any test performed before that was zero. Table 1 summarizes the percentage of syncope patients who underwent the different diagnostic tests at least once. The most commonly prescribed tests were a 12-lead ECG 98%, echocardiography 86%, and basic laboratory tests 86%. The five most commonly performed tests are all included in the initial evaluation according to the guidelines. Other tests included in the initial evaluation were orthostatic blood pressure movements (48%), carotid sinus massage (36%), tilt test (35%), and external loop recording (12%). However, tests that did not belong to the initial evaluation were also commonly used, e.g., exercise test (52%), MRI or CT scan (47%), neurological or psychiatric evaluation (47%), and EEG (39%). The highest costs per test were related to electrophysiology testing with £1391 per test (the weighted cost in PICTURE was £348, since 25% of patients underwent the test), followed by coronary angiography with £1285 (weighted cost £296, 23%) and electroencephalography with £180 (weighted cost £70, 39%).

Neurological investigations were common, which may be explained by the fact that a neurologist or a psychiatrist was frequently consulted as the first specialist. Eleven per cent of patients were referred to a neurologist as their first specialist, and in total 47% had seen a neurologist before the ILR implant. Probably as a consequence, neurological tests, such as EEG (39%) and MRI/CT (47%), were commonly prescribed, also in what the investigators described as early in the investigation. In the current guidelines, such investigations are only recommended when non-syncopal transient loss of consciousness (T-LOC) is suspected, most importantly when epilepsy is a likely or possible reason. Similarly, the number of patients undergoing more than one EEG and/or MRI/CT was high (Figure 4).

Contribution of repeated testing to the cost per patient

Some tests were repeated many times, meaning that sometimes even inexpensive tests, such as an ECG, contributed significantly to the costs. For example, a standard ECG and a Holter recording were very frequently repeated, and this was also the case with more expensive tests, e.g., exercise testing and tests that could be related to the frequent visits to neurologists (Figure 4). The pyramid plots in Figure 4 show how often the tests were performed and whether they were performed early or late. Considering the complicated care pathway for many patients, we may assume that more than one physician contributed when tests were repeated.

The diagnostic evaluation in PICTURE in relation to guideline recommendations

Since the study was entirely observational, there was nothing in the protocol or the case record forms to inform or guide the investigator about the current (2004) guidelines. However, the investigator was asked to indicate, by ticking a box, whether the implant, in his/her view, was performed ‘in an initial phase of diagnostic work-up of syncope’, i.e., early, or ‘after full evaluation of the mechanism of syncope’, i.e., late. The investigators classified 22.5% of the patients as having an early implant, whereas 67.7% had a late implant and the time-point was missing in 9.8% of the 570 patients. After the completion of the study, the early implants were compared with what the current guidelines included in the initial evaluation. We found that the proportion of patients who only had tests within the recommended initial evaluation was low, 12%, while there were many examples of over-investigation (Figure 5). The mean cost of diagnostic tests per patient in these 12% of patients was £709 compared with £1113 (95% CI £995 – £1232) in the entire study population.

Cost of the implantable loop recorder and the implant procedure

The UK reference costs are the best available proxy of the true costs of an ILR implant, and in 2009–10 the associated reference costs comparable to the percentage of other NHS hospitals. The cost of MRI/CT was calculated as half the sum of an MRI and a CT, since the study data did not differentiate between the two and we do not know the proportion of MRI and CT.
Table 2 Patient demographics

| Clinical features of syncope | All patients (N = 570) | Early implant (N = 128) | Late implant (N = 386) |
|-----------------------------|------------------------|-------------------------|------------------------|
| Hospitalized because of syncope | 370 (70.0%) | 68 (53.1%) | 291 (75.4%) |
| Any severe trauma (fractures, haemorrhage, etc.) | 204 (35.8%) | 29 (22.7%) | 151 (39.1%) |

Clinical features of last episode

| Position at the beginning of the episode | All patients (N = 570) | Early implant (N = 128) | Late implant (N = 386) |
|----------------------------------------|------------------------|-------------------------|------------------------|
| Supine | 52 (9.0%) | 12 (9.4%) | 37 (9.6%) |
| Sitting | 154 (27.0%) | 28 (21.9%) | 108 (28.0%) |
| Standing | 274 (48.0%) | 56 (43.8%) | 192 (49.7%) |
| Unknown | 83 (15.0%) | 29 (22.7%) | 45 (11.7%) |

Activity at the beginning of the episode

| Activity at the beginning of the episode | All patients (N = 570) | Early implant (N = 128) | Late implant (N = 386) |
|----------------------------------------|------------------------|-------------------------|------------------------|
| Rest | 294 (52.0%) | 42 (32.8%) | 223 (57.8%) |
| During effort | 144 (25.0%) | 44 (34.4%) | 89 (23.1%) |
| After effort | 28 (5.0%) | 7 (5.5%) | 15 (3.9%) |
| Unknown | 97 (17.0%) | 34 (26.6%) | 53 (13.7%) |

Symptoms during the episode

| Symptoms during the episode | All patients (N = 570) | Early implant (N = 128) | Late implant (N = 386) |
|----------------------------|------------------------|-------------------------|------------------------|
| Muscle spasms (one sided) | 8 (1.4%) | 4 (3.1%) | 2 (0.5%) |
| Muscle spasms (two sided) | 19 (3.3%) | 4 (3.1%) | 15 (3.9%) |
| Grand mal | 10 (1.8%) | 2 (1.6%) | 2 (1.3%) |
| Other muscle spasms | 14 (2.5%) | 2 (1.6%) | 10 (2.6%) |
| Transpiration | 73 (12.8%) | 19 (14.8%) | 47 (12.2%) |
| Cyanosis | 19 (3.3%) | 1 (0.8%) | 13 (3.4%) |
| Angina pectoris | 23 (4.0%) | 5 (3.9%) | 14 (3.6%) |
| Palpitations | 76 (13.3%) | 21 (16.4%) | 49 (12.7%) |
| Dizziness | 163 (28.6%) | 56 (43.8%) | 93 (24.1%) |
| Dyspnoea | 33 (5.8%) | 6 (4.7%) | 24 (6.2%) |
| Fatigue | 95 (16.7%) | 21 (16.4%) | 65 (16.8%) |

Comorbidity

| Comorbidity | All patients (N = 570) | Early implant (N = 128) | Late implant (N = 386) |
|-------------|------------------------|-------------------------|------------------------|
| Hypertension | 277 (48.6%) | 57 (44.5%) | 187 (48.4%) |
| Diabetes | 84 (14.7%) | 16 (12.5%) | 61 (15.8%) |
| Parkinson disease | 2 (0.4%) | 1 (0.8%) | 1 (0.3%) |
| Transient ischaemic attack (TIA) | 20 (3.5%) | 6 (4.7%) | 11 (2.8%) |
| Stroke | 37 (6.5%) | 5 (3.9%) | 25 (6.5%) |
| Other neurological disorder | 36 (6.3%) | 4 (3.1%) | 16 (4.1%) |

Structural heart disease

| Structural heart disease | All patients (N = 570) | Early implant (N = 128) | Late implant (N = 386) |
|--------------------------|------------------------|-------------------------|------------------------|
| Cardiomyopathy | 18 (3.2%) | 2 (1.6%) | 12 (3.1%) |
| Valvular heart disease | 30 (5.2%) | 5 (3.9%) | 24 (6.2%) |
| Coronary artery disease | 84 (14.7%) | 16 (12.5%) | 62 (16.1%) |
| Other | 29 (5.1%) | 4 (3.1%) | 18 (4.7%) |

Care pathway

| Profession of first consulted specialist hospital (n, %) | All patients (N = 570) | Early implant (N = 128) | Late implant (N = 386) |
|------------------------------------------------------|------------------------|-------------------------|------------------------|
| Cardiologist | 232 (41.0%) | 67 (52.3%) | 151 (39.1%) |
| Electrophysiologist | 12 (2.0%) | 3 (2.3%) | 9 (2.3%) |
| Cardiothoracic surgeon | 1 (0%) | 0 (0.0%) | 1 (0.3%) |
| Specialist for internal diseases | 100 (18.0%) | 12 (9.4%) | 88 (22.0%) |
| Emergency medicine | 133 (23%) | 24 (18.8%) | 95 (24.6%) |
| Imaging and radiologist | 3 (1%) | 1 (0.8%) | 2 (0.5%) |
| Neurologist | 63 (11.0%) | 14 (10.9%) | 35 (9.1%) |

All specialists seen in relation to syncope

| All specialists seen in relation to syncope | All patients (N = 570) | Early implant (N = 128) | Late implant (N = 386) |
|-------------------------------------------|------------------------|-------------------------|------------------------|
| General practitioner | 357 (62.6%) | 68 (53.1%) | 255 (66.1%) |
| Cardiologist | 521 (91.4%) | 121 (94.5%) | 348 (90.2%) |
| Electrophysiologist | 166 (29.1%) | 25 (19.5%) | 132 (34.2%) |

Continued
were £2606 (HRG EA03Z), including the device and all procedure costs and overheads such as staffing, catheterization laboratory utilization, disposable material, and hospital bed costs.

**Discussion**

The cost of investigation in patients with unexplained syncope varied greatly due to the number and type of tests performed per patient before the ILR implant. While some patients underwent many tests, which were often repeated, other patients received relatively little testing. The expenditure for some patients seems far too high, which most probably mainly reflects the lack of a structured care pathway. In this strictly observational registry, only 12% of the patients received tests entirely within the guideline recommendations for initial investigation before receiving the ILR, which is a very important finding, since it implies that the messages and recommendations of current guidelines are not known or at least not followed.

**Economic impact of unstructured vs. structured care pathways**

Although several previous reports agree that the economic impact of syncope management is substantial, the approaches and suggested solutions for reducing costs have varied. The creation of structured care pathways, inside or outside specific multidisciplinary syncope units, may lead to a uniform management according to pre-set guidelines and/or improved diagnostic and treatment algorithms. Specifically, approaches leading to fewer hospitalizations may be cost-effective as well as those leading to the appropriate use of available tests, avoiding both over- and under-investigations.

**What is an adequate care pathway and an adequate use of diagnostic tests?**

Overuse of diagnostic tests puts a burden on healthcare costs, but a prolonged and unsuccessful series of visits and diagnostic tests also cause patient frustration. Considering that arrhythmias are common causes in patients with unexplained syncope, an ILR implant early after the initial evaluation has been found a reasonable approach. Continuous ECG monitoring has a high chance of providing a symptom vs. rhythm correlation during the next syncope recurrence, which is crucial for determining the mechanism and guide subsequent appropriate treatment. The diagnostic tests of the initial evaluation of unselected syncope, including a standard ECG, echocardiography, carotid sinus massage in patients older than 40 years, and orthostatic blood pressure challenge, aim at identifying the most common causes of syncope, while those who remain undiagnosed after the initial evaluation may be defined as unexplained. In a clinical study, based on guidelines only 12% of unexplained syncope patients received an EEG and 14% a head CT.

While patients with unexplained syncope are more likely to have an underlying arrhythmia mechanism than unselected patients with syncope, arrhythmias causing syncope may occur at varying and often long intervals, giving standard ECGs and short-lasting ECG monitoring little chance of providing symptoms vs. ECG correlation when compared with continuous long-term ECG monitoring. Nevertheless, Holter monitoring was a very frequently used and often repeated test in PICTURE patients before the decision to implant an ILR, thus representing an inadequate use of available diagnostic tests. An earlier ILR implant rather than repetition of already non-diagnostic tests would seem more reasonable and is consistent with the current guidelines, with a good chance of being cost-effective in comparison with unstructured conventional testing.

Tests such as neurological evaluation or blood tests are only indicated when there is suspicion of non-syncope T-LOC, but are nevertheless often prescribed, also very early in the evaluation, the former probably because the symptoms frequently include various signs of convulsions. When described to the physician after the event, these symptoms might sound alarming enough to lead the early evaluation in a neurological direction, perhaps aiming to exclude or in some cases with the hope of confirming a neurological
cause, e.g. epilepsy. However, convulsions are common in syncope and the underlying mechanism is more likely to be clarified by symptom vs. ECG monitoring than with neurological tests. This likelihood increases in patients defined as having unexplained syncope. In studies using an ILR in unexplained syncope, \( \approx 80\% \) of the diagnostic yield was based on arrhythmias, including both brady- and tachycardias, that needed very different subsequent treatments.\(^{10,20}\) In contrast, the diagnostic yield using conventional diagnostic tests was only 12.5\%.\(^{20}\)

Can better adherence to guidelines influence the microeconomics of investigation of unexplained syncope?

In the 2004 version of the guidelines on the management of syncope, the implant of an ILR was presented as an option after an initial evaluation. Patients who had an early implant as defined by the investigators were most often more extensively investigated than recommended in the guidelines, but there was a significant difference as opposed to what the investigators regarded as a late implant. The observation that the diagnostic yield was similar supports that less investigation and lower costs for diagnostic tests before an earlier ILR implant can be achieved without losing diagnostic yield.

Possible effects of inadequate testing on other drivers of cost in unexplained syncope

Patients in PICTURE had had a median of four syncope events during a median of 2 years before their ILR implant. During this period, 70\% were at some time hospitalized for syncope and 36\% suffered severe trauma with fracture and/or bleeding. A long time between the first healthcare contact and diagnosis may reasonably increase the risk of recurrent syncope and syncope-related hospitalization and trauma.
An adequate investigation should ideally result in a correlation of symptoms vs. ECG. This is equally important in patients with and without an arrhythmia mechanism. While brady- and tachyarrhythmias have their specific treatment, patients with syncope during sinus rhythm, e.g. with psychogenic syncope, are also an important subgroup that will benefit from a correct diagnosis and information, which can subsequently help them to manage without further visits to healthcare facilities.

Cost of the implantable loop recorder and the implant procedure

As shown in our analysis of the PICTURE study, the frequent repetition of tests and the use of specific tests early in the investigation was a poor use of healthcare resources as they did not result in a diagnosis. At the same time, ILRs have been shown to be cost-effective in patients with unexplained syncope, implying that the higher initial costs should not discourage physicians from using an ILR when it is an option according to the current guidelines. In addition, a miniaturized ILR has recently become available, the Reveal LINQ, and due to its much smaller size a new insertion technique has made the implant procedure minimally invasive. As a consequence, this minimally
invasive procedure can be performed also in settings outside the catheterization laboratory, thus offering possibilities to reduce the procedure costs.

Limitations
We used UK data from 2010 to 2011 for reference. The cost level and reimbursement system may vary between countries and regions, but the relative difference in cost between tests is likely to be similar, which should make it possible to substitute our cost figures for other currencies to get valid estimations. The selected university hospital may not reflect other hospitals in all test procedures for unexplained syncope.

In addition, there is significant variation in the costs of treating individual patients, which is not reflected in this study. The times required for procedures, the grade of staff that usually administers the procedure, and the usual pathway were overall averages, gained from speaking to clinical staff either at the selected hospital, or where not available, from other UK hospitals. Again, these are likely to vary from patient to patient and from physician to physician.

Conclusions
This analysis of the microeconomics of the use of diagnostic tests in the PICTURE registry identified significant over-investigation in terms of both number and types of tests, especially in the initial phase of the evaluation. As a consequence, the analysis identified important opportunities to reduce test-related costs before an ILR implant by more appropriate use of tests recommended in the initial evaluation, by reducing frequent repetition of the same tests, and by avoiding early use of specific and expensive tests usually performed only on specific suspicions about the underlying mechanism. A structured multidisciplinary approach would have the best prerequisites to achieve an optimal result.

Conflict of interest: N.E. and N.J.L. are members of the Medtronic Speaker Bureau; C.W., S.T., and G.R. are employees of Medtronic.

Funding
The PICTURE registry was funded by Medtronic. Funding to pay the Open Access publication charges for this article was provided by Medtronic.

References
1. Sutton R, Benditt DG. Epidemiology and economic impact of cardiac syncope in western countries. Future Cardiol 2012;8:467–72.